• Antibiotic-Resistant E. coli in Urban Rodents: Insights from

  2026-04-30

  This study investigates the prevalence and resistance patterns of antimicrobial-resistant Escherichia coli found in urban rodents in Hanoi, Vietnam. The results underscore rodents as reservoirs for multidrug-resistant E. coli, posing potential risks for zoonotic transmission and public health.

• Alternariol-Induced Hepatic Stellate Cell Activation in Fibr

  2026-04-30

  This study provides direct mechanistic evidence that Alternariol (AOH) and related Alternaria toxins drive hepatic stellate cell (HSC) transdifferentiation into myofibroblasts, a central event in liver fibrosis. By integrating lncRNA-mRNA omics and pathway analysis, the authors identify key molecular signatures and propose a CotA laccase-based detoxification strategy, advancing mycotoxin research and risk management.

• GCG Disrupts SARS-CoV-2 Nucleocapsid Phase Separation to Inh

  2026-04-29

  The referenced study reveals that the SARS-CoV-2 nucleocapsid (N) protein undergoes RNA-triggered liquid–liquid phase separation (LLPS), a process essential for viral genome packaging and assembly. The polyphenol (-)-gallocatechin gallate (GCG) is shown to inhibit SARS-CoV-2 replication by disrupting this LLPS, highlighting a new molecular target for antiviral intervention.

• Cinoxacin in UTI Research: Optimized Workflows & Assay Strat

  2026-04-29

  Cinoxacin, a quinolone antibiotic from APExBIO, delivers robust, reproducible performance for urinary tract infection and antibiotic resistance research workflows. This guide provides actionable protocols, advanced troubleshooting, and comparative insights for maximizing assay reliability and translational value.

• CCG-1423: A Selective RhoA Inhibitor for Cancer and Viral Re

  2026-04-28

  CCG-1423 is a potent small-molecule RhoA inhibitor used in cancer research and cellular signaling studies. It targets MRTF-A/importin α/β1 interaction, suppresses cell proliferation, and modulates apoptosis. CCG-1423 enables precise dissection of RhoA/ROCK signaling, particularly in models of invasive cancer and viral pathogenesis.

• Intra- and Extracellular Dicloxacillin Action Against MSSA:

  2026-04-28

  This article highlights a seminal study dissecting the intra- and extracellular efficacy of dicloxacillin against methicillin-sensitive Staphylococcus aureus (MSSA) using both in vitro and in vivo models. The paper's integrated pharmacokinetic-pharmacodynamic analysis defines key experimental parameters and guides researchers on optimizing antibiotic evaluation for Gram-positive bacterial infection research.

• Transcription Condensate Dynamics Safeguard Genome Stability

  2026-04-27

  This study uncovers how cell cycle kinases and ATR-mediated checkpoint pathways coordinate the formation and dissolution of transcription condensates at histone locus bodies, balancing linker histone expression with DNA replication to maintain genome integrity. These insights refine our understanding of nuclear compartmentalization and highlight precise regulatory checkpoints essential for cancer and genome stability research.

• KPT-330 (Selinexor): Workflow Optimization in Cancer Researc

  2026-04-27

  KPT-330 (Selinexor), a selective CRM1 inhibitor, empowers oncology researchers to induce apoptosis and suppress tumor growth even in chemotherapy-resistant models. This article delivers actionable workflow enhancements, troubleshooting guidance, and translation of new combination therapy evidence for maximizing research outcomes with APExBIO’s KPT-330.

• Cardioprotective Mechanisms of Olive Oil Polyphenols: Focus

  2026-04-26

  This study dissects how extra virgin olive oil (EVOO) polyphenols—particularly hydroxytyrosol—modulate oxidative stress, inflammation, and cholesterol handling in cellular models. By comparing high-phenolic and standard EVOO extracts, the paper clarifies concentration-dependent effects on key cardiovascular pathways, offering mechanistic insights for antioxidant and anti-inflammatory research.

• DiscoveryProbe FDA-approved Drug Library: Accelerating HTS A

  2026-04-25

  The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) empowers researchers to identify and repurpose clinically validated compounds using robust, pre-dissolved solutions for high-throughput and high-content drug screening. This workflow-centric guide details how to harness the library for apoptosis-targeted cancer research, optimize screening protocols, and troubleshoot common assay challenges, with actionable insights derived from recent mechanistic studies.

• VX-745: Potent, Selective p38α MAPK Inhibitor for Inflammati

  2026-04-24

  VX-745 is a highly selective p38α MAPK inhibitor with nanomolar potency, enabling precise modulation of inflammation and cellular stress responses. Its unique mechanism facilitates both kinase inhibition and enhanced dephosphorylation, supporting robust applications in multiple myeloma, arthritis models, and cytokine signaling research.

• Naloxone Hydrochloride: Protocols for Opioid Receptor Antago

  2026-04-24

  Naloxone hydrochloride from APExBIO enables precise interrogation of opioid receptor signaling, neural stem cell proliferation, and addiction behaviors. This guide provides applied workflows, troubleshooting, and data-backed protocol parameters for advanced research in opioid antagonist mechanisms.

• Deracoxib and Piroxicam: Synergistic Inhibition in Canine Ma

  2026-04-23

  This study demonstrates that the combination of Deracoxib, a selective COX-2 inhibitor, and piroxicam produces synergistic cytotoxic and pro-apoptotic effects in canine mammary carcinoma cells. The findings highlight the enhanced efficacy of dual NSAID strategies for canine cancer models and inform protocol design in inflammation and oncology research.

• Cefazedone (Refosporen): Translational PK/PD Science & Clini

  2026-04-23

  Explore the translational pharmacokinetics and pharmacodynamics of Cefazedone (Refosporen), a first-generation cephalosporin antibiotic. Uncover unique insights into its PK/PD-driven clinical outcomes and advanced assay design, grounded in primary literature and expert protocol analysis.

• Deracoxib: Selective COX-2 Inhibitor for Inflammation Resear

  2026-04-22

  Deracoxib stands out as a selective COX-2 inhibitor, enabling reproducible inflammation and cancer biology assays in canine models. This guide bridges primary research insights, protocol optimization, and troubleshooting strategies to streamline your pain, inflammation, and oncology workflows with reliable, data-backed confidence.

16255 records 1/1084 page Next 12345 下5页 Last page